---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-133273"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T02:49:08.798164+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics terminates ATM prospectus; past sales $14.6M gross

## Summary
- On June 2, 2025, Trevi terminated the August 15, 2023 ATM prospectus with Leerink Partners.
- Sales Agreement remains in effect; no sales permitted until a new prospectus is filed.
- As of March 31, 2025, Trevi sold 4,498,065 shares for gross proceeds of ~$14.6M.
- No shares issued or sold under the Sales Agreement after March 31, 2025.
- Commissions and fees on past sales totaled approximately $0.5M.

## SEC filing metadata
- accession: 0001193125-25-133273
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000119312525133273/0001193125-25-133273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000119312525133273/d911843d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-133273
- JSON: https://secwatch.observer/filing/0001193125-25-133273.json
- Plain text: https://secwatch.observer/filing/0001193125-25-133273.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.